A drug that destroys the characteristic protein plaques that build up in the brains of patients with Alzheimer’s is showing “tantalising” promise, scientists say
Experts are cautious because the drug, Aducanumab, is still in the early stages of development.
But a study in Nature has shown it is safe and hinted that it halts memory decline.
Larger studies are now under way to fully evaluate the drug’s effects.
The build-up of amyloid in the brain has been a treatment target for many years.
However, there have been many disappointments in Alzheimer’s drug development, and it is over a decade since the last drug for people with the condition was licensed.
Other experts have welcomed this latest research – but with caution.